Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Managing director, the Foundry Group
VP of Research and Special Initiatives, Google
Director, Life Sciences Institute, University of Michigan
Dr. Celestia Higano, a prostate cancer specialist at the University of Washington and Fred Hutchinson Cancer Research Center, will be part of a live online chat from 11 am to Noon on May 4 at Seattletimes.com. Dr. Higano participated in the clinical trials for sipuleucel-T (Provenge), the first-of-its-kind immune booster for prostate cancer that was developed by Seattle-based Dendreon. The product won FDA approval on April 29, so it is just now becoming commercially available to terminally ill prostate cancer patients. To follow the conversation, click here.